Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-30
DOI
10.1038/s41598-020-62369-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
- (2018) Alireza Azimi et al. Molecular Systems Biology
- A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
- (2018) Janice M. Mehnert et al. Pigment Cell & Melanoma Research
- The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
- (2018) Bei Zhao et al. MELANOMA RESEARCH
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
- (2016) Luca Paoluzzi et al. Cancer Medicine
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
- (2015) Lijia Chen et al. ACS Medicinal Chemistry Letters
- The role of systemic therapies in the management of melanoma brain metastases
- (2014) Megan Lyle et al. CURRENT OPINION IN ONCOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
- (2014) N. Acquavella et al. Cancer Immunology Research
- Inhibiting drug efflux transporters improves efficacy of ALS therapeutics
- (2014) Michael R. Jablonski et al. Annals of Clinical and Translational Neurology
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer
- (2012) T. D. Prickett et al. CLINICAL CANCER RESEARCH
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma
- (2011) Ahmad Jalili et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
- (2011) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing
- (2010) Maria Gabriella Brasca et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- The MAPK pathway in melanoma
- (2009) Leslie A Fecher et al. CURRENT OPINION IN ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started